Sub-Q Bionics

Cover Block

PUBLIC

Attribute	Value
Company Name	Sub-Q Bionics
Tagline	Implantable bionic lymphatic drainage system for lymphedema
Headquarters	Stillwater, Minnesota, USA
Founded	2025
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-seed
Total Disclosed Funding	~$1,500,000 [Business Wire, March 2026]

Links

PUBLIC

• Website: https://subqbionics.com/
• LinkedIn: https://www.linkedin.com/in/karandeepbadwal/

Executive Summary

PUBLIC

Sub-Q Bionics is developing a fully implantable bionic system for chronic lymphedema, a condition where standard compression therapy often fails, and its recent pre-seed backing from a leading medical institution signals a credible, if early, clinical pathway [Business Wire, March 2026]. Founded in 2025, the company aims to address a persistent gap in oncology care by replacing external devices with a subcutaneous ceramic implant that uses an AI-enabled pump to drain fluid continuously into the peritoneum [Sub-Q Bionics website, 2026]. The founding team is led by Jordan Pollack, a biomedical engineer and serial founder based in Tel Aviv, though public details on the operational experience of the full team are limited [F6S, 2026]. The business model combines hardware sales with a software-enabled service layer, anchored by a $1.5 million pre-seed round closed in March 2026 with participation from Mayo Clinic and the Weizmann Institute's technology transfer arm, Yeda [Business Wire, March 2026]. Over the next 12-18 months, the critical watchpoints are the initiation of a planned $5 million seed round, the generation of first-in-human clinical data, and the translation of academic partnerships into a defined regulatory and commercial strategy.

Data Accuracy: YELLOW -- Core company claims and funding are cited, but some product and team details rely on single sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed (total disclosed ~$1,500,000)

Company Overview

PUBLIC

Sub-Q Bionics was founded in 2025 as a medical device company targeting chronic lymphedema [F6S]. The company is headquartered in Stillwater, Minnesota, and maintains a research and development presence in Israel, a structure reflected in its investor base [Business Wire, March 2026]. Its founding narrative centers on developing a fully implantable alternative to daily compression therapy for oncology patients, a wedge into a market dominated by external devices.

The company's first significant milestone was the close of a $1.5 million pre-seed round in March 2026. The round was led by Mayo Clinic, with participation from Yeda (the technology transfer company of the Weizmann Institute of Science), private investor Elie Eliachar, and matching funds from the Israel Innovation Authority [Business Wire, March 2026]. This capital is intended to advance the development of its ceramic subcutaneous implant system. The company has indicated plans to open a seed round targeting $5 million in the second quarter of 2026 [MedTech World, 2026].

Data Accuracy: YELLOW -- Key facts (founding year, funding, HQ) are confirmed by a primary press release and company profile, but some team details are sourced from a single, unverified platform.

Product and Technology

MIXED

Sub-Q Bionics is developing a fully implantable device for chronic lymphedema, a condition where the company's primary technical claim is to replace daily external compression with a single, permanent intervention. The core system, as described on the company website, consists of a ceramic subcutaneous implant that absorbs lymphatic fluid from a patient's limb and drains it into the peritoneal cavity using a subcutaneous, AI- and cloud-enabled pump [Sub-Q Bionics website]. The design targets a specific patient wedge: primarily women oncology survivors for whom standard compression therapy is intolerable or ineffective.

The proposed clinical workflow is notably streamlined. According to an F6S company profile, the implant procedure is claimed to take under one hour under local anesthesia, with an anticipated reduction in maintenance needs after three to six months [F6S]. This positions the product as a potential long-term management solution rather than a daily treatment. The integration of AI and cloud connectivity for pump control is a [PUBLIC] feature, though its specific algorithms and data usage policies are not detailed in public materials.

From an engineering standpoint, the combination of a biocompatible ceramic fluid-absorption component with an active, intelligent pump represents a significant hardware integration challenge. The technology appears to be in a pre-clinical or very early development stage, as no patient deployments or clinical trial data have been disclosed. The company's intellectual property foundation is suggested by its licensing agreement with Yeda, the technology transfer company of the Weizmann Institute of Science [YEDA Technology Transfer].

Data Accuracy: YELLOW -- Product claims are sourced from the company website and an F6S profile; technical feasibility and clinical claims are not yet independently verified.

Market Research

PUBLIC The chronic lymphedema treatment market is gaining investor attention as demographic and clinical trends expose the limitations of current standard-of-care therapies, creating a clear opening for novel, compliance-driven solutions. The condition, often a lifelong consequence of cancer treatments like lymph node removal, represents a persistent and growing burden on healthcare systems, with patient quality of life directly tied to the feasibility of daily management routines.

Third-party market research firms project consistent, high-single-digit to low-double-digit growth for the global lymphedema treatment sector over the next decade. SkyQuest Technology valued the market at $860.14 million in 2023, forecasting it to reach $1.9 billion by 2032 at a 9.5% compound annual growth rate [SkyQuest, 2026]. Data Bridge Market Research offers a slightly higher baseline and growth trajectory, citing a $1.05 billion valuation in 2024 with an expected climb to $2.30 billion by 2032, representing a 10.6% CAGR [Data Bridge Market Research, 2026]. A third report from The Insight Partners suggests a more aggressive potential expansion, projecting the market could reach $11.58 billion by 2028 [The Insight Partners, 2026]. While the absolute figures vary, the directional consensus points to a market doubling in size within the next eight years.

Demand is anchored by a rising global prevalence of cancer survivors, particularly breast cancer patients, who constitute the largest patient cohort for secondary lymphedema. The primary clinical tailwind is the documented patient non-compliance with existing pneumatic compression devices (PCDs) and manual drainage techniques, which are often cumbersome, time-consuming, and uncomfortable. This compliance gap creates the commercial wedge for any device that can demonstrably improve adherence through automation or reduced patient burden. Adjacent and substitute markets include the broader physical therapy and rehabilitation equipment sector, as well as the market for bioimpedance devices used for lymphedema detection and monitoring, a segment that has seen increased insurance coverage scrutiny [BCBSMS, 2026].

Regulatory pathways in the United States, primarily through the FDA's 510(k) or De Novo classification, present a significant gating factor for any new implantable device. Macro forces are favorable, however, driven by an aging population, improving cancer survival rates, and a growing focus on value-based care models that reward interventions reducing long-term complications and hospital visits. Reimbursement remains a critical unknown, as securing CPT codes and favorable payer policies for a novel implant will be a multi-year endeavor crucial for commercial adoption.

2023 (SkyQuest) | 860.14 | $M
2032 (SkyQuest) | 1900.22 | $M
2024 (Data Bridge) | 1050 | $M
2032 (Data Bridge) | 2300 | $M
2028 (The Insight Partners) | 11580 | $M

The chart illustrates the range of market sizing projections, from a conservative doubling to a more speculative tenfold increase. The variance underscores the uncertainty in forecasting a niche medical device market but consistently signals strong underlying growth drivers. For an early-stage company, the more conservative SkyQuest and Data Bridge figures likely represent a more actionable serviceable market.

Data Accuracy: YELLOW -- Market sizing figures are cited from third-party research reports, but specific methodology and primary data sources are not disclosed. The growth trend is corroborated across multiple independent analyses.

Competitive Landscape

MIXED Sub-Q Bionics enters a lymphedema treatment market defined by established, non-invasive device incumbents and a handful of startups exploring more advanced interventions.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Sub-Q Bionics	Fully implantable, AI-enabled ceramic pump for continuous fluid drainage.	Pre-seed, $1.5M (Mar 2026)	Fully subcutaneous, aims for reduced maintenance after 3-6 months.	[Business Wire, March 2026]
Koya Medical	Non-pneumatic compression device (NPCD) for active, dynamic compression.	Venture-backed	Wearable, non-pneumatic design shown more effective than standard pneumatic devices in a recent study.	[Medical Device Network, 2026]
Tactile Medical	Provider of pneumatic compression devices (PCDs) for at-home lymphedema management.	Publicly traded (Nasdaq: TCMD)	Established reimbursement pathways and broad commercial footprint.	[PUBLIC]
ImpediMed	Bioimpedance spectroscopy (BIS) devices for early detection and monitoring of lymphedema.	Publicly traded (ASX: IPD)	Focus on early detection and objective measurement, not active treatment.	[BCBSMS, 2026]
Fibralign (BioBridge)	Bioabsorbable scaffold to guide tissue regeneration and restore lymphatic flow.	Private	Surgical implant designed to promote natural lymphatic regeneration, not a mechanical pump.	[PUBLIC]

The competitive map splits into three distinct segments. The largest, non-invasive pneumatic compression, is dominated by Tactile Medical and other durable medical equipment providers. These are the standard of care, reimbursed, and widely prescribed, but they require daily patient compliance with external garments. A newer challenger in this space is Koya Medical, whose non-pneumatic, dynamic compression device represents an evolution of the external therapy model with recent clinical validation [Medical Device Network, 2026]. The second segment focuses on diagnostics and monitoring, where ImpediMed's bioimpedance technology is used for early detection and tracking, creating a potential upstream funnel for treatment devices. The third, most surgically invasive segment includes regenerative approaches like Fibralign's scaffold and Sub-Q Bionics' active pump, both targeting patients for whom external therapy has failed.

Sub-Q Bionics' defensible edge today is its clinical and research backing, not commercial traction. The pre-seed round was led by Mayo Clinic and included Yeda, the technology transfer arm of the Weizmann Institute [Business Wire, March 2026]. This signals early validation from premier clinical and research institutions, a critical asset for navigating the FDA's Class III device pathway. The technical differentiator, a fully subcutaneous ceramic pump with AI-enabled fluid management, is a unique architectural bet. This edge is durable only if the team can translate it into a reliable, manufacturable implant with a compelling safety profile in human trials. It is perishable if surgical complications, pump failures, or fibrosis around the implant materialize in early studies, or if a well-capitalized incumbent like Medtronic or Boston Scientific decides to acquire a similar regenerative technology instead.

The company is most exposed in the commercial channel and the surgical adoption curve. Tactile Medical and other incumbents own the durable medical equipment (DME) distributor relationships and payer reimbursement codes that define the current market. Sub-Q Bionics would need to build an entirely new reimbursement category for an implantable pump, a multi-year process. Furthermore, its success depends on convincing vascular or plastic surgeons to adopt a new, irreversible implant procedure. This contrasts with Koya Medical's strategy, which stays within the familiar compression therapy paradigm and thus faces a lower adoption barrier for both clinicians and payers.

The most plausible 18-month scenario sees further stratification between external and implantable solutions. Koya Medical is positioned to be a winner if payer reimbursement for its NPCD device expands following its positive clinical data, allowing it to capture share from traditional pneumatic devices [Medical Device Network, 2026]. Sub-Q Bionics, meanwhile, faces a binary outcome. It could emerge as a compelling, high-risk/high-reward candidate for a strategic partnership if its seed round funds successful animal studies and an IDE application. However, it is a potential loser if those early technical milestones are delayed, leaving it undercapitalized against the steep costs of a first-in-human trial while competitors solidify their positions in less invasive segments.

Data Accuracy: YELLOW -- Competitor profiles are assembled from public sources and trade press; Sub-Q Bionics' differentiation is cited from its own materials and funding announcement.

Opportunity

PUBLIC The prize for Sub-Q Bionics is a dominant position in a high-value segment of the chronic disease management market, where its fully implantable system could command premium pricing and recurring revenue from a patient population with limited therapeutic alternatives.

The headline opportunity for Sub-Q Bionics is to become the standard of care for refractory lymphedema, a condition where existing external therapies fail or are intolerable. The company's core bet is that a permanent, subcutaneous device requiring minimal patient intervention will unlock a new treatment paradigm for the estimated 20-30% of lymphedema patients who are non-compliant with compression therapy [PMC, 2026]. This outcome is reachable because the clinical need is well-documented and the early backing of Mayo Clinic provides a credible pathway to clinical validation and adoption [Business Wire, March 2026]. The opportunity is not merely to sell a device, but to establish a new treatment protocol for a chronic condition, creating a recurring service model around device monitoring, AI-driven pump optimization, and potential future upgrades.

Growth scenarios outline specific, concrete paths to scale beyond the initial clinical foothold.

Scenario	What happens	Catalyst	Why it's plausible
Oncology Partnership Standard	The device becomes a recommended or bundled post-operative solution for breast cancer survivors at major cancer centers.	A published clinical outcomes study from Mayo Clinic or a similar institution demonstrating superior quality-of-life metrics.	Mayo Clinic is already an investor, signaling intent to clinically integrate the technology [Business Wire, March 2026]. The target patient is explicitly the oncology survivor unable to use compression [Sub-Q Bionics].
Platform Expansion into Chronic Edema	The core fluid-drainage technology is adapted for other forms of chronic edema (e.g., cardiac, renal).	FDA clearance for the initial lymphedema indication, creating a regulatory pathway for adjacent claims.	The physiological mechanism (draining fluid to the peritoneum) is not lymphedema-specific. The implantable form factor and AI pump represent a platform that could be tuned for different fluid accumulation pathologies.

What compounding looks like for Sub-Q Bionics is a clinical data flywheel. Each implanted device generates continuous, real-world data on lymphatic fluid dynamics and pump performance. This dataset, proprietary to the company, would be used to refine the AI algorithms that control the pump, theoretically improving efficacy and reducing adverse events over time. Superior outcomes would drive further surgeon adoption and payer reimbursement, which in turn deploys more devices and enriches the dataset. The company's claim of an "AI- and cloud-enabled subcutaneous pump" suggests this flywheel is a foundational part of the product design from the outset [Sub-Q Bionics]. While no clinical data has been published yet, the architecture is built to create a data moat that competitors without an implanted, connected device would struggle to replicate.

The size of the win can be framed by looking at acquisition multiples in the adjacent medical device space. Tactile Medical, a public company focused on home-based lymphedema therapy devices, achieved a market capitalization of approximately $300 million in early 2026. A company that successfully defines a new, implant-based standard of care for refractory patients could plausibly command a significant premium, targeting a valuation in the high hundreds of millions to low billions (scenario, not a forecast). This is supported by the underlying market growth, with the lymphedema treatment sector projected to reach between $1.9 billion and $2.3 billion by 2032 [SkyQuest, 2026] [Data Bridge Market Research, 2026]. Sub-Q Bionics would be capturing the highest-acuity, highest-cost segment of that expanding market.

Data Accuracy: YELLOW -- The market size projections are from third-party reports. The clinical need and target patient segment are cited from medical literature and the company's own materials. The growth scenarios are logical extrapolations based on the company's stated focus and investor base, but lack specific, forward-looking partnership announcements.

Sources

PUBLIC

1. [Business Wire, March 2026] Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care | https://www.businesswire.com/news/home/20260330377271/en/Sub-Q-Bionics-Closes-$1.5M-Pre-Seed-Round-to-Advance-Next-Generation-Solution-for-Lymphedema-Care

2. [Sub-Q Bionics website, 2026] Sub-Q Bionics , https://subqbionics.com/

3. [F6S, 2026] Sub-Q Bionics Inc , https://www.f6s.com/company/sub-q-bionics-inc

4. [MedTech World, 2026] A new chapter in lymphedema care , https://med-tech.world/news/sub-q-bionics-seed-round-lymphedema/

5. [SkyQuest, 2026] Lymphedema Treatment Market Report | Not available

6. [Data Bridge Market Research, 2026] Global Lymphedema Treatment Market Report | Not available

7. [The Insight Partners, 2026] Lymphedema Treatment Market Report | Not available

8. [Medical Device Network, 2026] Koya’s NPCD device proves more effective than APCDs in lymphedema , https://www.medicaldevice-network.com/news/koyas-npcd-device-proves-more-effective-than-apcds-in-lymphedema/

9. [BCBSMS, 2026] Bioimpedance Devices for Detection and Management of Lymphedema , https://www.bcbsms.com/policy-search/medical/policy-detail/bioimpedance-devices-for-detection-and-management-of-lymphedema

10. [PMC, 2026] Results from a comparative study ... (TEAYS study) , https://pmc.ncbi.nlm.nih.gov/articles/PMC11764854/

11. [YEDA Technology Transfer] Sub-Q Bionics Licensing Agreement , https://www.yedarnd.com/news-search